

Appendix A: Medications Used in Palliative Care for Dyspnea and Respiratory Secretions

Tailor dose to each patient; those who are elderly, cachectic, debilitated or with renal or hepatic dysfunction may require reduced dosages; consult most current product monograph for this information: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php

OPIOIDS ^A								
Generic Name	Trade Name	Available Dosage Forms	Standard Adult Dose (opioid-naïve) ^B	Drug Plan Coverage ^c		Approx. cost per		
				Palliative Care	Fair PharmaCare	30 days D		
hydromorphone	Dilaudid®, G	IR tabs: 1, 2, 4, 8 mg	0.5-1 mg PO q4h	Yes, LCA	Yes, LCA	\$9–18 (G) \$9–18		
		Inj: 2 mg/mL	0.25-0.5 mg SC q4h	Yes	Yes	\$1–2 per amp (2 mg/mL)		
morphine	MS-IR®, Statex®	IR tabs: 5, 10, 20, 25, 30, 50 mg	2.5-5 mg PO q4h	Yes, LCA	Yes, LCA	\$11–21		
		Inj: 1, 2, 5, 10, 15, 25, 50 mg per mL	Crisis dyspnea: 5 mg IV/SC q5– 2.5-5 mg PO. Titrate to q4h 10 min. Double dose if no effect every third dose	Yes	Yes	\$2 per amp (10 mg/mL)		
oxycodone	Oxy IR®, Supeudol®, G IR tabs: 5, 10, 20 mg	IR tabs: 5, 10, 20 mg	2.5-5 mg PO. Titrate to q4h	Yes, LCA	Yes, LCA	\$13–25 (G) \$26–53		

Morphine Equivalence Table (for chronic dosing)							
DRUG	SC/IV (mg)	PO (mg)	COMMENTS				
morphine	10	30 ^A					
hydromorphone	2	4					
oxycodone	not available in Canada	20					

A Health Canada recommends using a conversion of 10 mg SC/IV morphine = 30 mg PO (1:3) Refer to http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14603a-eng.php

			BENZODIAZEPINES			
Generic Name	Trade Name	Available Dosage Forms	Standard Adult Dose	Drug Plan Coverage ^c		Approx. cost per
				Palliative Care	Fair PharmaCare	30 days ^D
lorazepam	Ativan®, G	Tabs : 0.5, 1, 2 mg	0.5-2 mg PO/ sublingual q2-4h PRN	Yes, LCA	Yes, LCA	\$0.04-0.08 (G) \$0.04-0.10 per tablet
		Sublingual tabs: 0.5, 1, 2 mg		Yes, LCA	Yes, LCA	\$0.10-0.20 (G) \$0.13-0.25 per tablet
		Inj: 4 mg per mL	0.5-2 mg SC ^E q2-4h PRN	Yes	Yes	\$22.90 per 1 mL vial
midazolam	G	Inj: 1 mg per mL, 5 mg per mL	2.5-5 mg SC ^E q5-15 min prn	Yes, LCA	No	\$0.84/mL (1 mg/mL vial) \$4.43/mL (5 mg/ mL vial)
			NEUROLEPTICS			
metho- trimeprazine	G	Tabs: 2, 5, 25, 50 mg	2.5-5 mg PO q8h, titrate to effect	Yes, LCA	Yes, LCA	\$5–10 (G)
	Nozinan [®]	Inj: 25 mg/mL	6.25 mg SC q8h, titrate to effect	Yes	Yes	\$3.74/amp (25 mg/mL)
			CORTICOSTEROIDS			
dexamethasone	G	Tabs: 0.5, 0.75, 2, 4 mg	8-24 mg PO/SC ^E /IV every morning, taper if possible	Yes, LCA	Yes, LCA	\$20–59 (G)
		Inj: 4, 10 mg per mL		Yes, LCA	Yes, LCA	\$54–328 (G)
		MEDICATION	IS FOR RESPIRATORY	SECRETIONS		
atropine	G	Inj: 0.4, 0.6 mg per mL	0.2-0.8 mg SC q4h and q1h PRN	Yes	Yes	\$2.50–5 (G) per dose
		Drops: 1% solution	1 to 4 drops sublingual ^E q4h prn	No	Yes	\$3.75 per 5 mL bottle
glycopyrrolate	G	Inj: 0.2 mg per mL	0.2-0.4 mg SC ^E / sublingual ^E /PO ^E q4h to q8h	Yes	Yes	\$26–52 (G) per 24 h

Abbreviations: G generics; h hour; inj injection; IR Immediate Release; PO by mouth; PRN as needed; SC subcutaneous; SR slow release; tabs tablets

^A Not an exhaustive list. Other opioids may be appropriate.

^B For opioid-tolerent patients, increase current dose by 25-50%.

^c PharmaCare coverage as of October 2016 (subject to revision). Obtain current coverage, eligibility, and coverage information from the online BC PharmaCare Formulary Search page at pharmacareformularysearch.gov.bc.ca

Cost as of October 2016 and does not include retail markups or pharmacy fees. Generic and brand name cost separated as indicated by (G).

^E This route of administration is used in practice, but not approved for marketing for this indication by Health Canada